A price for cost-effectiveness: implications for recombinant human activated protein C (rhAPC).
Chalfin
Donald B
DB
Teres
Daniel
D
Rapoport
John
J
D000890:Anti-Infective Agents / Q000191:economics* / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D017048:Health Care Costs; D006801:Humans; D011486:Protein C / Q000191:economics* / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000191:economics* / Q000627:therapeutic use; D018805:Sepsis / Q000188:drug therapy*; D014481:United States
D000890:Anti-Infective Agents; D011486:Protein C; D011994:Recombinant Proteins; C421124:drotrecogin alfa activated